GH Peptides & HGH in BC — What's Legal, What Works, and Where to Get It (2026)
Few categories of longevity medicine generate more confusion in BC than growth hormone optimization. The reader has heard about Sermorelin from a podcast, seen Ipamorelin/CJC-1295 advertised by a Vancouver wellness clini...
Sarah K., MSc Health Sciences
BCMedicalAccess.ca Editorial Team
GH Peptides & HGH in BC — What's Legal, What Works, and Where to Get It (2026)
Last Updated: April 2026
Reviewed by Sarah K., MSc Health Sciences | BCMedicalAccess.ca Editorial Team
⚠️ Important Notice
This article is for informational purposes only and does not constitute medical advice. BCMedicalAccess.ca is a healthcare navigation resource, not a medical provider. Consult a licensed physician before pursuing any hormone or peptide therapy.
Introduction
Few categories of longevity medicine generate more confusion in BC than growth hormone optimization. The reader has heard about Sermorelin from a podcast, seen Ipamorelin/CJC-1295 advertised by a Vancouver wellness clinic, and likely encountered "research peptide" suppliers shipping injectables straight to a residential address. Somewhere in the same conversation, human growth hormone (HGH) gets mentioned — usually with claims that mix legitimate adult GHD treatment with anti-aging marketing.
The legal landscape is genuinely confusing, and it changed materially in April 2026. Health Canada has now issued two separate advisories — April 2025 and April 2026 — naming specific peptides as unauthorized drugs, and provincial colleges of physicians have begun publishing guidance to clinicians [1,2]. What was a regulatory grey zone is becoming substantially less grey, particularly for the GH peptides this article covers.
This guide is informational, not medical advice. It explains what these substances are, what the human evidence shows, what's legal in BC right now, and what the legitimate access pathways look like.
What Are GH Peptides? (vs. HGH)
The growth hormone (GH) axis is straightforward: the hypothalamus releases growth hormone-releasing hormone (GHRH), which signals the pituitary to release growth hormone, which signals the liver to produce insulin-like growth factor-1 (IGF-1), which mediates most of GH's downstream effects. Two intervention strategies exist.
Growth hormone secretagogues are peptides that stimulate the pituitary to release more of your own growth hormone. They work upstream — preserving the natural pulsatile release pattern and the body's negative-feedback loops. Exogenous HGH (somatropin) is recombinant human growth hormone administered directly. It bypasses the hypothalamus and pituitary entirely, delivering a flat, non-pulsatile concentration of GH.
The choice between them is not stylistic. Secretagogues tend to produce smaller, more physiological IGF-1 elevations. Exogenous HGH produces larger elevations and stronger effects, but with greater risk of suppressing endogenous production and a higher side-effect profile.
| Compound | Class | Mechanism | Health Canada status |
|---|---|---|---|
| Sermorelin | Secretagogue (GHRH analog, 29 aa) | Stimulates pituitary GH release | No DIN; original Geref discontinued |
| Ipamorelin | Secretagogue (selective ghrelin agonist) | Triggers GH pulse without raising cortisol/prolactin | No DIN; named in April 2026 advisory |
| CJC-1295 | Secretagogue (long-acting GHRH analog) | Sustained GHRH-receptor activation | No DIN; named in April 2026 advisory |
| BPC-157 | Tissue-repair peptide (not GH axis) | Animal-model healing effects | No DIN; named in 2025 and 2026 advisories |
| TB-500 (Thymosin β-4) | Tissue-repair peptide (not GH axis) | Actin regulation, repair signalling | No DIN; named in April 2026 advisory |
| Somatropin (HGH) | Exogenous recombinant GH | Direct GH replacement | Approved for specific indications; multiple DINs (Genotropin, Norditropin, etc.) |
BPC-157 and TB-500 are commonly grouped with "peptide therapy" but are not GH-axis compounds. They appear here because BC patients researching GH peptides routinely encounter them in the same clinic conversations. (For NAD+, also frequently included in these conversations: NAD+ is a nucleotide, not a peptide, and is covered separately in our NAD+ IV therapy guide.)
Legal Status in Canada & BC
This is the section that has changed the most in the past year, and the section that most marketing-oriented content does not present accurately.
Regulatory framework. Injectable peptides are regulated as prescription drugs in Canada [3]. (Note: the older "Schedule F" terminology is obsolete — Health Canada replaced Schedule F with the Prescription Drug List in 2013. Both terms refer to the same regulatory status.) For an injectable peptide to be sold legally in Canada, it must hold a Drug Identification Number (DIN) issued by Health Canada and be dispensed through a licensed pharmacy on a valid prescription. Authorized peptide drugs in Canada include semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), and somatropin under various brand names. None of the GH peptides discussed in this article — Sermorelin, Ipamorelin, CJC-1295 — currently hold a DIN. Neither do BPC-157 or TB-500.
Health Canada's April 9, 2026 advisory is the most important fact for BC residents to understand. Health Canada explicitly named the following as unauthorized injectable peptide drugs that should not be purchased or used: BPC-157, CJC-1295, DSIP, Epitalon, GHK-Cu, HCG, HGH and HGH Fragment, Ipamorelin, KPV, Melanotan I and II, MOTS-C, NAD+, SS-31, TB-500, and Retatrutide [1]. Health Canada had previously seized unauthorized peptides from suppliers including Prime Research (Quebec) in April 2025 and Canada Peptide more recently [2,4].
The "research chemical" loophole is not legal cover. Health Canada has been unambiguous: labelling a product "for research use only" does not exempt it from regulation, and selling unauthorized injectables to consumers is illegal in Canada [3]. Independent testing of online research peptides has documented contamination, incorrect peptide content, and dosing inaccuracies — the safety risks are real, not theoretical.
Somatropin (HGH) holds DIN-authorized status, but only for specific approved indications: pediatric and adult growth hormone deficiency confirmed by stimulation testing, Turner syndrome, Prader-Willi syndrome, chronic kidney disease in children, idiopathic short stature, short stature due to small-for-gestational-age birth, and HIV/AIDS wasting (Serostim) [5]. HGH for adult anti-aging is not an approved indication in Canada. A BC physician prescribing HGH outside approved indications takes on professional risk under CPSBC oversight.
What BC physicians can prescribe. A CPSBC-licensed physician can write a prescription for somatropin within approved indications, filled at any pharmacy. For peptides without DINs (Sermorelin, Ipamorelin, etc.), a physician may write a prescription routed to a Health Canada-licensed compounding pharmacy that compounds the peptide for that specific patient. This compounding pathway has historically been used in BC, but its regulatory status is now actively contested. The College of Physicians and Surgeons of Alberta issued professional guidance in April 2026 cautioning physicians about prescribing the same peptides Health Canada had named [6]. The CPSBC has not issued an equivalent BC-specific notice as of this writing, but Canadian physician colleges typically move in alignment, and clinical practice is shifting accordingly.
What the Evidence Says
Sermorelin and Ipamorelin/CJC-1295 for adult GHD and body composition. Sermorelin was originally FDA-approved as Geref in the 1990s for pediatric growth hormone deficiency before the branded product was discontinued in 2008 [7]. The molecule itself reliably elevates IGF-1 in GH-deficient patients — that's not in dispute. What's much weaker is the evidence base in healthy adults using these peptides for body-composition or anti-aging purposes. The 2024 FDA Pharmacy Compounding Advisory Committee briefing concluded that no growth hormone secretagogue, including ipamorelin, has been approved for adult GHD treatment, and that randomized human data in healthy adults is limited [8]. Patients commonly report improved sleep within 1–2 weeks and modest body-composition shifts over months, though randomized placebo-controlled trial data supporting these effects in healthy adults is sparse.
BPC-157 for tissue repair. Animal evidence is genuinely impressive — over 100 preclinical studies suggest accelerated healing of tendons, ligaments, and gut lining [9]. Human evidence is not. A 2025 systematic review in the American Journal of Sports Medicine screened 544 articles for orthopaedic indications and found only one clinical study meeting inclusion criteria [10]. BPC-157 has never been approved by any regulatory agency anywhere in the world.
TB-500 (Thymosin Beta-4) for recovery. Better human data than BPC-157 — Phase 2 trials of thymosin beta-4 eye drops in severe dry eye disease showed meaningful improvement at day 56 [11], and Phase 1 safety trials of synthetic TB-4 at doses up to 1,260 mg over 14 days showed no serious adverse events [12]. None of these studies, however, evaluated the musculoskeletal indications most patients are seeking.
Exogenous HGH for adult GHD. This is the indication with the strongest evidence on this list. Multiple randomized trials in patients with confirmed adult GHD show improvements in body composition, lipid profile, bone density, and quality-of-life scores after 6–12 months of replacement therapy [13]. The catch is that the evidence applies specifically to deficient patients — adults with GH levels confirmed inadequate on stimulation testing. Evidence that HGH improves outcomes in healthy adults with normal age-related decline is much weaker, and the 2007 Annals of Internal Medicine meta-analysis remains influential: in healthy elderly adults, HGH produced small body-composition changes alongside elevated rates of soft-tissue edema, joint pain, gynecomastia, and impaired glucose tolerance [14].
The honest summary: GH peptides have a plausible mechanistic story, mixed-to-thin human evidence in healthy adults, and a regulatory environment that has tightened materially. Exogenous HGH has clear utility in genuine deficiency and a poor risk-benefit profile in healthy adults seeking anti-aging effects.
Who Is a Candidate?
Genuine candidates for GH peptide or HGH therapy are narrower than marketing language suggests.
The strongest case is adult growth hormone deficiency confirmed by appropriate diagnostic workup — usually IGF-1 measurement followed by GH stimulation testing (insulin tolerance test, glucagon stimulation, or macimorelin). Most patients with adult GHD have an underlying cause: pituitary adenoma, prior cranial radiation, traumatic brain injury, or sequelae of childhood-onset GHD. These patients should be managed by an endocrinologist, not a wellness clinic.
A weaker but defensible case exists for symptomatic patients with low-normal IGF-1, persistent fatigue or recovery problems, and contributing factors (chronic poor sleep, overtraining, prolonged caloric restriction). Some BC physicians will trial GH-stimulating peptides in this population after thorough workup; others decline given the regulatory environment.
Who should not pursue GH peptide or HGH therapy: anyone with active or recent malignancy (GH and IGF-1 support proliferation pathways), uncontrolled diabetes (GH antagonizes insulin), active retinopathy, intracranial hypertension, or severe obesity unrelated to GHD. Competitive athletes subject to anti-doping testing should not use these compounds — all are on the World Anti-Doping Agency Prohibited List [15]. Anyone whose primary motivation is reversing normal age-related decline should know that the evidence is thin and the side-effect profile is real.
For broader hormone optimization context, see our companion guide on TRT in BC.
How to Access Peptide Therapy in BC
A legitimate clinical pathway has four stages.
Step 1: Baseline bloodwork. Before any prescription is written, a comprehensive panel is essential: IGF-1 (the primary GH-axis biomarker), fasting glucose and HbA1c, complete metabolic panel including liver and kidney function, lipid panel, full thyroid (TSH, free T4, free T3), sex hormones (testosterone, estradiol, SHBG), and a CBC. For suspected adult GHD, formal GH stimulation testing is the diagnostic standard — a single IGF-1 reading is not sufficient. See our overview on private testing options at private lab testing in BC for cost ranges. Expect $200–$450 for a baseline panel; stimulation testing is usually arranged through endocrinology referral.
Step 2: Physician consultation. Several BC clinics offer longevity-focused or hormone-optimization consultations — examples include Connect Health (Vancouver), Gravity Health (Vancouver), and Men's Vitality Clinic (Vancouver) [16]. These clinics operate outside MSP for the consultation portion and bill privately. Initial consultations typically run 60–90 minutes covering medical history, contraindication screening, goal-setting, and lab review. A reputable consultation will not promise a prescription before assessment, and will be transparent about the regulatory environment around the specific peptide you're inquiring about. For a broader directory, see our clinic directory.
Step 3: Prescription and dispensing. If you qualify for somatropin (HGH) under approved indications, the prescription is filled at any pharmacy. For compounded peptides such as Sermorelin, the prescription is routed to a Health Canada-licensed compounding pharmacy. Given Health Canada's April 2026 advisory, BC clinicians and compounding pharmacies are increasingly conservative about which peptides they will prescribe and compound. Sermorelin remains the most likely to be available through legitimate pathways given its longer regulatory history; Ipamorelin, CJC-1295, BPC-157, and TB-500 face elevated scrutiny.
Step 4: Ongoing monitoring. A responsible protocol re-checks labs at 8–12 weeks. IGF-1 is the central tracking marker — sustained levels above the age-adjusted reference range are what you want to avoid. Glucose, HbA1c, blood pressure, and side-effect screening (joint pain, edema, paresthesias) are checked at each follow-up. Cycling protocols (3 months on, 4–6 weeks off) are commonly used to maintain receptor sensitivity, though evidence for specific cycling regimens is empirical rather than RCT-validated. For more on longevity monitoring, see our longevity hub.
Cost in BC (2026)
| Item | Estimated cost |
|---|---|
| Initial physician consultation | $150–$350 |
| IGF-1 bloodwork (private) | $80–$200 |
| Comprehensive baseline panel (private) | $200–$450 |
| GH stimulation test (specialist setting) | $200–$500 |
| Sermorelin (compounded, monthly) | $200–$400 |
| Ipamorelin/CJC-1295 stack (compounded, monthly) | $300–$600 |
| HGH / somatropin (Genotropin, Norditropin, etc.) | $1,000–$2,500/month |
| Quarterly follow-up consultation | $150–$300 |
A typical first-year cost for someone on a sustained Sermorelin or CJC-1295/Ipamorelin protocol with quarterly monitoring runs $5,000–$8,500. Patients on full somatropin replacement therapy can exceed $20,000/year. Coverage is essentially nonexistent: BC Medical Services Plan (MSP) does not cover peptide therapy, and somatropin is covered only for narrow approved indications via Special Authority. Private extended health plans rarely cover compounded peptides; somatropin coverage typically requires the same Special Authority approval as PharmaCare. Off-label HGH for anti-aging is universally denied.
FAQ
Is peptide therapy legal in BC?
It depends on the peptide. Some peptides (semaglutide, tirzepatide, somatropin, liraglutide) are fully approved Health Canada drugs with DINs and are legal by prescription. Others — including Sermorelin, Ipamorelin, CJC-1295, BPC-157, and TB-500 — do not have DINs and were named in Health Canada's April 9, 2026 public advisory as unauthorized injectable peptide drugs [1]. Compounded preparations through licensed compounding pharmacies on a physician's prescription have historically operated as a pathway, but the regulatory environment is tightening. Selling unauthorized peptides directly to consumers is illegal in Canada.
Can I buy peptides online in Canada?
Online "research peptide" suppliers commonly market products with the disclaimer "for research use only — not for human consumption." This labelling does not make the products legal — Health Canada has explicitly stated it does not exempt them from regulation [1]. Health Canada has seized unauthorized peptides from multiple Canadian suppliers (Prime Research in 2025, Canada Peptide in 2026) [2,4]. Independent testing has documented contamination and dosing inaccuracies in these products. Self-injecting peptides obtained outside the prescription framework places you outside any regulated supply chain — meaning no purity guarantee, no sterility verification, and no medical oversight if something goes wrong.
Does MSP cover growth hormone therapy?
MSP and BC PharmaCare cover somatropin only for approved Health Canada indications — confirmed pediatric or adult growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, chronic kidney disease in children, and a few related diagnoses — and only after Special Authority approval based on physician documentation [5]. HGH for adult anti-aging, body composition, or athletic performance is not covered under any circumstance. Compounded GH-stimulating peptides (Sermorelin, Ipamorelin, etc.) are not covered by MSP, BC PharmaCare, or the vast majority of private extended health plans. Expect peptide therapy to be cash-pay throughout.
What's the difference between peptides and HGH?
Growth hormone secretagogues (Sermorelin, Ipamorelin, CJC-1295) are peptides that stimulate the pituitary to release more of your own GH. They work upstream, preserving the natural pulsatile release pattern and the body's feedback regulation. Exogenous HGH (somatropin) is recombinant human growth hormone administered directly — it bypasses the hypothalamus and pituitary, producing larger but non-physiological elevations of GH and IGF-1. Secretagogues generally have a milder side-effect profile and lower risk of suppressing your own production; HGH has stronger effects but a higher side-effect burden, including edema, joint pain, insulin resistance, and risk of carpal tunnel symptoms.
How long before I see results from peptide therapy?
Most patients on GH-stimulating peptides report improved sleep quality within 1–2 weeks — typically the first noticeable change. Subjective changes in energy and recovery often appear by week 4–6. Measurable body-composition shifts (lean mass, body fat) typically require 3–6 months and are modest in healthy adults — most published data shows changes in the single-digit-percent range rather than dramatic transformation. IGF-1 elevation can be confirmed on bloodwork by week 4. Patients who see no measurable benefit by month 4 are unlikely to be strong responders and should discuss with their physician whether to continue, adjust, or stop.
References
[1] Health Canada. Public Advisory: Think twice before injecting peptides bought online — unauthorized products can seriously harm you. April 9, 2026. https://recalls-rappels.canada.ca/en/alert-recall/think-twice-injecting-peptides-bought-online-unauthorized-products-can-seriously-harm
[2] Health Canada. Public Advisory: Unauthorized injectable peptide drugs sold by Prime Research may pose serious health risks. April 14, 2025.
[3] Government of Canada. Food and Drug Regulations — Prescription Drug List framework. https://www.canada.ca/en/health-canada.html
[4] Health Canada. Unauthorized injectable peptide drugs seized and sold by Canada Peptide may pose serious health risks. 2026.
[5] Canadian Agency for Drugs and Technologies in Health (CADTH/CDA-AMC). Somatropin Health Technology Review — approved indications and reimbursement criteria.
[6] College of Physicians and Surgeons of Alberta. Unauthorized injectable peptides and their potential serious health risks — guidance for physicians. April 2026.
[7] U.S. Food and Drug Administration. Geref (sermorelin acetate) NDA 020443 — discontinued product record.
[8] U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Briefing Document — Ipamorelin and CJC-1295. 2024.
[9] Perkovic M et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. International Journal of Molecular Sciences, 2025.
[10] DeFoor MT, Dekker TJ. Injectable therapeutic peptides — an adjunct to regenerative medicine and sports performance? A 2025 systematic review. American Journal of Sports Medicine / Arthroscopy, 2025;41(2):150–152.
[11] Sosne G, Dunn SP, Kim C. Thymosin Beta-4 Significantly Improves Signs and Symptoms of Severe Dry Eye in a Phase 2 Randomized Trial. Cornea, 2015.
[12] Crockford D et al. Phase I clinical trial of recombinant and synthetic thymosin beta-4 in healthy volunteers. Annals of the New York Academy of Sciences, 2010.
[13] Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism, 2011;96(6):1587–1609.
[14] Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Annals of Internal Medicine, 2007;146(2):104–115.
[15] World Anti-Doping Agency. Prohibited List — S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics, current edition.
[16] Connect Health (Vancouver), Gravity Health (Vancouver), Men's Vitality Clinic (Vancouver) — BC longevity and hormone optimization clinic websites, accessed April 2026. All physicians named on these sites are CPSBC-licensed.
Disclaimer
This article is for informational purposes only and does not constitute medical advice. BCMedicalAccess.ca is a health information directory, not a medical provider. Always consult a licensed physician before starting any hormone or peptide therapy. For health emergencies, call 911 or HealthLinkBC at 811.
Last Updated: May 4, 2026
Reviewed by BCMedicalAccess.ca Editorial Team — content reviewed for accuracy and compliance with BCMedicalAccess.ca editorial standards.